When Commercial Manufacturing Serves Dozens, Not Thousands

Key Takeaways

• Commercial manufacturing no longer implies high volume: For ultra-rare and highly specialized therapies, “commercial scale” is defined by regulatory permanence and life cycle obligations, not throughput.

• Ultra-low-volume programs strain traditional CDMO economics: Fixed costs, campaign manufacturing burdens, and validation requirements do not scale down proportionally with batch size.

• Batch sizing and validation become strategic, not tactical, decisions: Early choices shape comparability, continued process verification, and long-term supply resilience.

• Cost transparency matters more than per-unit pricing: Campaign-based and capacity-aware pricing models better reflect the realities of ultra-low-volume commercial manufacturing.

• Supporting the smallest markets is a defining CDMO capability: The ability to sustain reliable, compliant supply for structurally small commercial programs is becoming a key test of modern CDMO operating models.

For much of pharma’s history, “commercial scale” functioned as shorthand for volume. A product crossed the regulatory finish line, demand expanded, and manufacturing followed a familiar arc toward larger batches, greater throughput, and increasing efficiency. That model still holds for many drug products, but it no longer captures the reality of a growing segment of approved therapies.

However, commercial designation increasingly reflects regulatory status and permanence rather than unit count. Approval signals that a therapy has moved beyond development and into an ongoing obligation to supply patients reliably, sometimes for the remainder of their lives. That obligation does not disappear simply because the patient population is small. Nor does it relax expectations around quality systems, control strategies, or life cycle oversight. Commercial manufacturing, in this context, is defined less by throughput than by durability: the expectation that product will be available when needed, year after year, even if the total number of patients can be counted in the dozens.

Public assessments of ultra-rare therapies make this shift visible. In the United Kingdom, for example, highly specialized therapies have been evaluated in settings where the total number of eligible patients in England was estimated in the tens to low hundreds, with some programs addressing far fewer individuals annually.^1,2 The policy framework governing these evaluations explicitly anticipates such scenarios, with eligibility criteria designed for conditions affecting very small populations rather than large, expandable markets.³ In these cases, approval does not imply future scale-up; it formalizes a commitment to serve a fixed and limited group of patients over time.

This gives rise to structurally small commercial programs. These programs are not early launches waiting for demand to materialize or pilots intended to inform broader rollout. They are inherently bounded by disease prevalence, diagnostic rates, and clinical eligibility. Annual production volumes may remain stable or intermittent across the product’s life cycle, yet the designation and obligations associated with commercial status remain fully in force.

For contract development and manufacturing organizations (CDMOs), this distinction is foundational. Episodic clinical support is typically organized around flexibility and short time horizons. Structurally small commercial programs require a different posture oriented toward continuity, long-term process stewardship, and sustained readiness. Recognizing that commercial manufacturing no longer automatically implies scale is a necessary starting point for understanding why ultra-low-volume programs challenge conventional operating assumptions, and why they warrant distinct manufacturing strategies.

It is tempting to view ultra-low-volume commercial programs as an extension of late-stage clinical manufacturing. Volumes are small, production runs are infrequent, and teams are often familiar with the process from pivotal or registration-enabling studies. From a distance, the operational footprint can look similar. In practice, however, the assumptions that govern late-stage clinical manufacturing diverge meaningfully from those that define commercial supply, even when patient numbers remain limited.

Late-stage clinical manufacturing is inherently transitional. Processes are still being refined, specifications may evolve, and manufacturing strategies are built around the expectation that change is likely and acceptable. By contrast, ultra-low-volume commercial manufacturing is defined by permanence. Approval fixes product labeling within defined boundaries, establishes post-approval commitments, and creates an ongoing obligation to supply patients indefinitely. Even when annual demand is measured in single digits or dozens, manufacturers are expected to demonstrate life cycle control through appropriate validation strategies and continued process verification.⁴ The infrequency of production does not reduce the expectation that the process remains capable and that changes are assessed systematically over time.

That permanence reshapes operational priorities. Commercial products must be manufactured to consistently meet approved specifications with limited tolerance for informal adjustments. Stability programs continue, comparability becomes a recurring consideration, and quality systems must function effectively across long gaps between batches without erosion of process knowledge or oversight. In rare disease settings, U.S. Food and Drug Adminstration (FDA) guidance explicitly recognizes that patient populations may be extremely small, but it does not suggest that the responsibilities associated with commercial status diminish as a result.⁵

Operational shortcuts that may be manageable during clinical phases often fail under these conditions. Documentation practices that rely heavily on institutional memory become risky when years separate production campaigns, and ad hoc deviations can accumulate into comparability challenges when opportunities to generate new data are scarce. Once a product is commercial, such approaches are difficult to defend, regardless of volume.

CDMOs that treat ultra-low-volume commercial programs as “clinical-plus” frequently encounter friction as these differences surface. What initially appears to be a familiar, low-intensity engagement can evolve into a long-term obligation that strains systems designed for either high-throughput commercial manufacturing or short-lived clinical work. Ultra-low-volume commercial manufacturing is neither a scaled-down version of commercial nor an extended clinical exercise, and these programs demand operating models built for durability, regulatory accountability, and continuity rather than transition.

Batch size is often framed as a response to demand, but in ultra-low-volume commercial manufacturing, demand is rarely the binding constraint. Instead, CDMOs operate around a minimum viable batch size defined by what a process can reliably support under existing technical and regulatory conditions. For structurally small commercial programs, that minimum is shaped by factors that do not shrink proportionally as volumes decline, particularly equipment performance limits and quality system requirements.

Most manufacturing platforms have practical lower bounds below which behavior becomes unstable or insufficiently characterized. Mixing efficiency, hold times, filtration performance, and fill accuracy can shift as batch sizes approach the edges of a system’s operating range. Even when smaller vessels or single-use configurations are available, the process must still generate enough material to demonstrate control, support in-process testing, and absorb routine losses without jeopardizing supply.

Yield loss and sampling requirements further constrain how small a batch can be. Every commercial run must accommodate material consumed by in-process controls, release testing, stability pulls, and retains. At very low volumes, these fixed requirements can represent a substantial fraction of total output, narrowing the margin between what is technically feasible and what is operationally sensible. Small yield deviations that would be manageable at larger scales can quickly erode that margin.

These constraints introduce overage and discard risk that is often underestimated early in a program. Producing only what is nominally needed may appear efficient, but CDMOs frequently build in additional material to protect against unforeseen losses, recognizing that a failed batch can delay patient access for extended periods. That protective overage further distances batch size from demand and reinforces the role of technical and quality considerations as the dominant sizing drivers.

Importantly, “right-sizing” batches does not lead to a linear reduction in cost or complexity. Many activities associated with a commercial batch, including preparation, documentation, quality review, and release, occur regardless of scale. As batch sizes shrink, these fixed elements account for a larger share of total effort. Smaller batches may reduce raw material consumption, but they do little to simplify the surrounding operational framework and can even increase complexity by pushing processes into less familiar operating regimes.

Early batch-size decisions therefore carry life cycle consequences. The selected scale influences validation strategies, shapes the data available for continued process verification, and affects how easily changes can be assessed over time.⁴ A batch size chosen solely to meet immediate supply needs may later constrain comparability assessments or limit flexibility as analytical methods evolve. For ultra-low-volume commercial programs, batch sizing is not a tactical adjustment but a foundational choice that ripples across manufacturing, quality, and long-term supply planning.

Campaign manufacturing is often presented as a way to create efficiency by grouping similar activities and reducing repetitive setup. In a low-volume commercial context, however, campaigns serve a different purpose. Rather than maximizing throughput, they function as a risk-management and compliance strategy, allowing CDMOs to concentrate infrequent production into defined windows that can support the full range of commercial requirements. When batch sizes are small, the campaign becomes less about scale and more about containment: containing disruption, complexity, and cumulative operational burden.

What becomes apparent quickly is how many elements of a campaign do not scale down with volume. Line clearance must still be executed to the same standards, regardless of whether a run produces thousands of units or a few dozen. Changeover activities, including cleaning, verification, and documentation, consume roughly the same calendar time even as output shrinks. Environmental monitoring continues throughout the campaign, and quality assurance review and batch release follow the same pathways and controls that apply to higher-volume products, with little opportunity for simplification once a product is commercial.

Changeover illustrates the imbalance between effort and output. Extended changeover periods directly reduce productive capacity and affect facility utilization, independent of the size of the subsequent run.⁶ In an ultra-low-volume setting, that impact is amplified. A campaign may occupy a week or more of preparation, execution, and closeout while yielding only a small amount of finished product, but it consumes the same physical space, personnel, and quality resources required for larger programs.

This dynamic creates meaningful opportunity cost. Calendar time becomes a scarce resource as campaigns for small programs compete with higher-volume products for access to shared infrastructure. Inflexibility increases as campaigns are scheduled well in advance to ensure availability of trained staff, qualified equipment, and quality oversight. Once committed, these windows are difficult to compress or reschedule without ripple effects across the broader manufacturing calendar.

As a result, ultra-low-volume campaigns can disproportionately consume capacity relative to the output they generate. Evaluated on a per-batch basis, they may appear inefficient or misaligned with traditional utilization metrics. However, when evaluated at the portfolio level, they represent a deliberate allocation of capability to support products that are commercially small but clinically and strategically significant. CDMOs that recognize this distinction are better positioned to integrate such programs without destabilizing the rest of the portfolio, while those that do not often struggle to reconcile fixed campaign demands with expectations shaped by higher-volume norms.

Cost allocation is often where expectations diverge most sharply between sponsors and CDMOs in ultra-low-volume commercial programs. Traditional pricing models assume that costs can be distributed across units, grams, or doses, with efficiency improving as scale increases. When volumes fall to the level of dozens of patients per year, that arithmetic stops working. The underlying cost structure does not disappear; it becomes concentrated.

At very low volumes, the distinction between variable, and fixed costs becomes unavoidable. Variable costs, such as raw materials and consumables, decline as output falls but often represent only a fraction of the total effort required to manufacture a commercial batch. Fixed and semi-fixed costs dominate. Quality oversight, engineering support, validation activities, documentation, and facility overhead are largely insensitive to batch size. Whether a campaign yields a large commercial lot or a very small one, the same systems must be engaged to prepare, execute, review, and release the batch.

This imbalance is particularly visible in advanced therapies. Per-patient costs remain high even before commercial margins are considered, driven primarily by labor-intensive processes and extensive quality controls rather than material inputs alone.⁷ While such analyses are not specific to commercial supply, they illustrate a broader principle that applies across modalities: in GMP manufacturing, cost is anchored in infrastructure, expertise, and compliance as much as in volume.

As a result, traditional per-unit or per-gram pricing can produce misleading signals. Dividing total costs by a small number of units may yield figures that appear disproportionate, even when they accurately reflect the work required. Efforts to benchmark ultra-low-volume programs against higher-volume products often shift the burden rather than remove it. In practice, many CDMO portfolios absorb part of this mismatch through implicit cross-subsidies, either within a modality or across programs with steadier throughput. These cross-subsidies are rarely visible, but they influence portfolio economics and shape which programs can be supported sustainably.

To navigate these constraints, some CDMOs adopt pricing approaches that align more closely with operational impact. Campaign-based pricing ties fees to discrete manufacturing windows rather than output. Capacity-reservation models acknowledge the opportunity cost of dedicating facility time and personnel to infrequent runs. Service-bundle structures group manufacturing, quality, and life cycle support into integrated offerings that reflect the full scope of ongoing obligations. These approaches do not eliminate cost pressure, but they make it more transparent and predictable.

For drug developers, this context is critical in pricing discussions. Ultra-low-volume commercial manufacturing is rarely expensive because of inefficiency or excessive margin. It is expensive because regulatory and quality expectations remain constant, even when there are few patients to absorb the cost. CDMOs often manage this tension quietly, balancing mission-driven programs against portfolio realities. Understanding that dynamic enables more constructive engagement and supports operating models that can sustain structurally small commercial programs over time.

Ultra-low-volume commercial programs place validation at the intersection of regulatory expectation and physical constraint. The governing framework remains life cycle–based, with process design, process qualification, and continued process verification forming a continuous system rather than a one-time hurdle.4 What changes is not the obligation to validate but the way evidence is generated and sustained when opportunities to run batches are limited.

Scarcity of material heightens the tension between statistical confidence and practical feasibility. Conventional validation approaches rely on repeated production to demonstrate consistency and control. When only a small number of commercial batches can be produced each year, sampling plans, acceptance criteria, and trend analysis must operate with fewer data points spread over longer intervals. Long gaps between runs can complicate interpretation and increase reliance on historical knowledge and disciplined data management.

CDMOs adapt by placing greater emphasis on process understanding and continuity over time. Robust characterization during process design becomes more important because it establishes the scientific basis for later decisions. Rather than relying solely on discrete validation runs, evidence is built longitudinally, with data aggregated across batches, campaigns, and extended timeframes. Continued process verification assumes a central role, supported by enhanced monitoring, careful trend analysis, and structured change management to compensate for the limited volume of new data generated in any single period.

These adaptations do not mean reduced rigor. GMP responsibilities apply in full, regardless of how many units are produced. Documentation must remain complete and defensible, and control strategies must be clearly articulated and consistently applied. In rare disease contexts, regulators recognize the practical constraints associated with very small populations but do not suggest that commercial standards can be relaxed once a product is approved.⁵

The practical outcome is a different evidence strategy rather than a lighter one. Validation becomes less about achieving a prescribed number of batches and more about demonstrating continuity, understanding, and control across the life cycle. For ultra-low-volume commercial products, success depends on aligning validation plans with the realities of limited material while preserving the rigor expected of any commercial therapy.

Although ultra-low-volume commercial manufacturing shares common operational challenges across modalities, cell and gene therapies and biologics introduce distinct stress points that shape how those challenges manifest in practice. Recognizing these differences is essential for CDMOs seeking to support structurally small programs without overextending platforms designed for very different production profiles.

For cell and gene therapies, manufacturing is often single-patient or tightly patient-linked, even after approval. This structure compresses timelines and amplifies the consequences of disruption. Release windows can be narrow, driven by cell viability, scheduling of clinical procedures, or logistics constraints. Opportunities for repetition are limited because each run may differ meaningfully in starting material, timing, or execution.

Cost exposure compounds these pressures. Public analyses of cell and gene therapy manufacturing consistently show that per-patient costs are driven less by materials than by labor intensity, quality oversight, and facility demands, all of which remain largely fixed regardless of how many patients are treated.⁷ In a commercial setting, a single failed or delayed batch can therefore have outsized financial and clinical impact, raising the stakes of every run even when total annual volume is minimal.

Biologics present a different but equally challenging set of constraints. Stability and shelf-life considerations limit how far production can be decoupled from demand, particularly for products that cannot be stockpiled easily. Infrequent commercial runs increase the importance of maintaining analytical methods, reference standards, and process knowledge across long intervals. Comparability becomes a recurring concern as changes must be assessed against a relatively sparse manufacturing history.

Scale-down models play a central role in addressing these challenges, but they must be robust enough to support commercial justification, not just development decisions. When batches are rare, sponsors and CDMOs rely heavily on small-scale data to inform risk assessments and change management, placing additional pressure on the scientific rationale linking those models to commercial performance.

These modality-specific stress points underscore why a purely modality-agnostic infrastructure is rarely sufficient. Flexible platforms help, but they do not eliminate the need for targeted expertise, tailored control strategies, and operating models that reflect how risk concentrates differently in cell and gene therapy and biologics. For ultra-low-volume commercial programs, success depends less on generic capability and more on alignment between modality-specific realities and CDMO design.

For sponsors, ultra-low-volume commercial manufacturing introduces strategic decisions that differ in both scale and consequence from those associated with more conventional products. The small size of the market can make these programs appear manageable when viewed through a development lens. In practice, however, the intersection of commercial obligations and fixed manufacturing demands demands choices that are aligned with long-term operational realities rather than near-term convenience.

Often, the first inflection point involves decisions around outsourcing versus internal build. For structurally small programs, the economics of building and maintaining dedicated internal capability can be difficult to justify, particularly when production is infrequent and specialized expertise is required. Outsourcing to a CDMO can provide access to established quality systems, experienced personnel, and infrastructure that would otherwise be underutilized. At the same time, reliance on an external partner introduces dependencies that must be managed over the full life cycle of the product, not just through launch. Sponsors must therefore weigh not only immediate cost considerations, but also the stability and strategic fit of the operating model over time.

Partnering strategy presents a related tradeoff. A single-partner approach can simplify communication and support continuity of process knowledge. Multi-partner strategies may offer redundancy or modality-specific strengths, but they introduce additional complexity in technology transfer, change management, and comparability. In ultra-low-volume settings, where opportunities to generate new data are limited, each additional interface increases coordination and documentation burdens.

Sponsors also tend to underestimate the cumulative operational load associated with small commercial programs. Infrequent manufacturing does not equate to low effort. Maintaining readiness between runs, preserving trained teams, sustaining validated states, and managing ongoing quality obligations all require sustained attention. Cost predictability can be challenging when expenses are driven by fixed activities rather than output and when campaigns must be scheduled well in advance to secure capacity.

Early manufacturing strategy choices shape these dynamics. Decisions about batch size, facility selection, and partner engagement influence validation approaches and affect how easily changes can be managed over time. For sponsors, aligning manufacturing strategy with the realities of ultra-low-volume commercial programs is essential to maintaining reliable supply over the long term.

What This Means for CDMOs

Ultra-low-volume commercial programs challenge some of the most entrenched assumptions in CDMO operations, and they are not a natural fit for every organization. While the clinical importance of these therapies is clear, the operational and economic realities they impose require a level of intentionality that extends beyond technical capability alone. For many CDMOs, the more difficult question is not whether they can support such programs, but whether doing so aligns with their broader operating strategy.

Portfolio strategy sits at the center of that decision. Capacity mix matters, particularly in facilities where high-throughput commercial products and structurally small programs share infrastructure. Ultra-low-volume campaigns can occupy disproportionate calendar time and quality resources while contributing relatively little to overall output. Without careful planning, they can introduce scheduling volatility and strain teams optimized for steady-state production. CDMOs must assess how many such programs their portfolios can absorb without eroding performance elsewhere.

Technical specialization also plays a decisive role. Supporting ultra-low-volume commercial manufacturing often requires deep familiarity with specific modalities, processes, or control strategies, especially when opportunities to relearn or refine execution are rare. Generalist capabilities may be sufficient for development or early clinical work, but they can fall short when commercial expectations extend over long intervals with little margin for error. Organizations that succeed in this space tend to concentrate expertise rather than dispersing it thinly across platforms.

Equally important is organizational tolerance for inefficiency, at least as measured by traditional metrics. Ultra-low-volume programs rarely optimize utilization or cost per unit. Their value lies in sustaining supply for patients who have no alternatives. CDMOs must therefore be prepared to evaluate success using broader criteria, including reliability, compliance, and strategic fit, rather than throughput alone.

These factors point toward operating models designed for durability and readiness rather than scale. In a landscape where structurally small commercial programs are becoming more common, alignment between portfolio strategy and operating model will determine which CDMOs can support them sustainably.

Ultra-low-volume commercial manufacturing forces a reconsideration of what “commercial” truly means. In a growing number of cases, approval no longer signals the beginning of scale but the start of a long-term obligation to deliver highly specialized therapies to very small patient populations. Volume may be limited, but expectations are not. Regulatory accountability, supply continuity, and quality rigor apply in full, even when demand is measured in dozens rather than thousands.

Meeting these expectations requires operational realism. Batch sizes are constrained by technical and quality considerations, campaigns carry fixed burdens that do not diminish with output, and validation strategies must be built around scarcity rather than abundance. Economic honesty is equally important. The cost structures that underpin commercial manufacturing do not collapse at low volumes, and attempts to force them into traditional per-unit frameworks often obscure the real drivers of effort and risk. Models that acknowledge fixed costs and opportunity costs are better suited to sustaining these programs over time.

Ultra-low-volume commercial manufacturing also demands a life cycle–aware strategy. Decisions made early, from batch sizing to partner selection, shape the evidence that can be generated, the flexibility available for change, and the resilience of the supply chain years into the future. For sponsors and CDMOs alike, success depends on recognizing that these programs are neither transitional nor peripheral, but a durable category of commercial manufacturing with its own operating logic.

As rare and highly specialized therapies continue to reach patients, ultra-low-volume manufacturing will become less of an exception and more of a proving ground. The ability to support the smallest markets reliably and sustainably is emerging as a defining test of modern CDMO capability, one that reflects not just technical proficiency, but strategic alignment with the evolving realities of biopharmaceutical development and care.

1. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations. National Institute for Health and Excellence. Aug. 2019.

2. Strimvelis for the treatment of adenosine deaminase deficiency-severe combined immunodeficiency. National Institute for Health and Excellence. 28 Sep. 2017.

3. Duddy, Claire and Nikki Sutherland. “Debate on innovation in the field of rare retinal disease.” House of Commons. 22 Jan. 2025.

4. Process Validation: General Principles and Practices: Guidance for Industry. U.S. Department of Health and Human Services. Jan. 2011.

5. Rare Diseases: Considerations for the Development of Drugs and Biological Products. U.S. Food and Drug Administration. Dec. 2023.

6. Feliciano, Kelly M Barreto. “Improving Product Changeover in Pharmaceutical Manufacturing Through Lean Six Sigma.” Polytechnic University of Puerto Rico. Oct. 2024.

7. Lopes, Adriana G, Andrew Sinclair, and Bert Frohlich. “Cost Analysis of Cell Therapy Manfuacture: Autologous Cell Therapies, Part 1.” BioProcess International. 27 Mar. 2018.